Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611001283965
Ethics application status
Approved
Date submitted
15/12/2011
Date registered
15/12/2011
Date last updated
15/12/2011
Type of registration
Retrospectively registered

Titles & IDs
Public title
Use of serial 18F-fluorodeoxyglucose (FDG) and 18F-fluorothymidine (FLT) positron emission tomography (PET) & computed tomography (CT) for candidates with non-small cell lung cancer (NSCLC)receiving radical chemo-radiation therapy
Scientific title
A prospective study to investigate the impact of serial FDG and FLT PET scans on the radiation therapy treatment of patients with NSCLC
Secondary ID [1] 273607 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
lung cancer 279356 0
Condition category
Condition code
Cancer 285543 285543 0 0
Lung - Non small cell

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
FDG and FLT PET/CT scans at baseline, during week two and week four of therapy.
Each scan involves the injection of a radiotracer (FDG or FLT).
Each scan is approximately 30 minutes in duration.
Patients will be recruited over a five year period.
Intervention code [1] 283863 0
Not applicable
Comparator / control treatment
Observational single arm study, standard treatment adminstered.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 286109 0
To simulate the administration of biologically adapted radiation therapy (BART) to patients with NSCLC using information gained from interim FLT & FDG PET/CT scans.
Timepoint [1] 286109 0
Following recruitment of all patients
Secondary outcome [1] 295166 0
To determine the role of interim FLT & FDG PET/CT scans as biomarkers of patient prognosis.
Timepoint [1] 295166 0
Overall survival (OS): time from first RT treatment until death from any cause.
Progression free survival (PFS): time from first RT until progression (local, regional & distant).
OS and PFS will be assessed clinically and with diagnostic imaging, including a follow-up FDG PET/CT scan.

Eligibility
Key inclusion criteria
Written informed consent provided.
Histologically or cytologically confirmed NSCLC.
Candidate for radical RT (60Gy) & concomitant chemotherapy (standard regimen determined by medical oncologist).
Stage I - III disease (TNM 7th edition).
ECOG performance status 0-1.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Received previous thoracic RT or a complete macroscopic excision of tumour.
Pregnancy (Women of child-bearing age to ensure adequate contraceptive measures).

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
23/10/2008
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 284342 0
Government body
Name [1] 284342 0
NHMRC
Country [1] 284342 0
Australia
Funding source category [2] 284343 0
Government body
Name [2] 284343 0
Victorian Cancer Agency
Country [2] 284343 0
Australia
Primary sponsor type
Hospital
Name
Peter MacCallum Cancer Centre
Address
St Andrews Place
East Melbourne
VIC 3001
Country
Australia
Secondary sponsor category [1] 283283 0
University
Name [1] 283283 0
University of Melbourne
Address [1] 283283 0
Grattan Street
Parkville
Melbourne
VIC 3010
Country [1] 283283 0
Australia
Other collaborator category [1] 260377 0
University
Name [1] 260377 0
Monash University
Address [1] 260377 0
Dept Medical Imaging and Radiation Sciences
Wellington Road
Clayton,
VIC 3800
Country [1] 260377 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 286300 0
Peter MacCallum Cancer Centre
Ethics committee address [1] 286300 0
Ethics committee country [1] 286300 0
Australia
Date submitted for ethics approval [1] 286300 0
Approval date [1] 286300 0
14/10/2008
Ethics approval number [1] 286300 0
08/40
Ethics committee name [2] 286338 0
Monash University
Ethics committee address [2] 286338 0
Ethics committee country [2] 286338 0
Australia
Date submitted for ethics approval [2] 286338 0
Approval date [2] 286338 0
23/10/2008
Ethics approval number [2] 286338 0
2008001483

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33513 0
Address 33513 0
Country 33513 0
Phone 33513 0
Fax 33513 0
Email 33513 0
Contact person for public queries
Name 16760 0
Sarah Everitt
Address 16760 0
Radiation Therapy
Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
VIC 8006
Country 16760 0
Australia
Phone 16760 0
61 3 96561111
Fax 16760 0
Email 16760 0
[email protected]
Contact person for scientific queries
Name 7688 0
Sarah Everitt
Address 7688 0
Radiation Therapy
Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
VIC 8006
Country 7688 0
Australia
Phone 7688 0
61 3 96561111
Fax 7688 0
Email 7688 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Study results articleYes Everitt S, Ball D, Hicks R, Callahan J, Plumridge ... [More Details]

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AISpleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy2015https://doi.org/10.1371/journal.pone.0142608
EmbaseCone-beam computed tomography for lung cancer - validation with CT and monitoring tumour response during chemo-radiation therapy.2017https://dx.doi.org/10.1111/1754-9485.12551
Dimensions AIAcute radiation oesophagitis associated with 2-deoxy-2-[18F]fluoro-d-glucose uptake on positron emission tomography/CT during chemo-radiation therapy in patients with non-small-cell lung cancer2017https://doi.org/10.1111/1754-9485.12631
EmbaseWhat18F-FDG PET response-assessment method best predicts survival after curative-intent chemoradiation in non-small cell lung cancer: EORTC, PERCIST, Peter Mac criteria, or Deauville criteria?.2019https://dx.doi.org/10.2967/jnumed.118.214148
EmbaseNodal metabolic tumour volume on baseline 18F-FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative-intent chemoradiotherapy/radiotherapy.2021https://dx.doi.org/10.1111/1754-9485.13294
EmbaseBlood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients.2022https://dx.doi.org/10.3390/cancers14010257
N.B. These documents automatically identified may not have been verified by the study sponsor.